Iranian Red Crescent Medical Journal

Published by: Kowsar

The Survey of Her2/neu Expression and It’s Correlation with Some Pathological Factors in Urothelial Bladder Tumors

Samane Danaei 1 , Seyed Hamid Madani 1 , * , Sedigheh Khazaei 1 , Babak Izadi 1 , Elahe Saleh 2 and Soraya Sajadimajd 3
Authors Information
1 Molecular Pathology Research Center, Imam Reza University Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
2 Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
3 Fertility and Infertility Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
Article information
  • Iranian Red Crescent Medical Journal: February 2018, 20 (2); e58494
  • Published Online: February 27, 2018
  • Article Type: Research Article
  • Received: July 22, 2017
  • Revised: December 10, 2017
  • Accepted: February 14, 2018
  • DOI: 10.5812/ircmj.58494

To Cite: Danaei S, Madani S H, Khazaei S, Izadi B, Saleh E, et al. The Survey of Her2/neu Expression and It’s Correlation with Some Pathological Factors in Urothelial Bladder Tumors, Iran Red Crescent Med J. 2018 ; 20(2):e58494. doi: 10.5812/ircmj.58494.

Abstract
Copyright © 2018, Iranian Red Crescent Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
References
  • 1. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J. Cancer incidence in five continents, Volume IX. IARC Press, International Agency for Research on Cancer; 2007.
  • 2. Hsairi M, Fakhfakh R, Ben Abdallah M, Jlidi R, Sellami A, Zheni S, et al. [Assessment of cancer incidence in Tunisia 1993-1997]. Tunis Med. 2002;80(2):57-64. [PubMed: 12080555].
  • 3. Bolenz C, Shariat SF, Karakiewicz PI, Ashfaq R, Ho R, Sagalowsky AI, et al. Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. BJU Int. 2010;106(8):1216-22. doi: 10.1111/j.1464-410X.2009.09190.x. [PubMed: 20089105].
  • 4. Gandour-Edwards R, Lara PJ, Folkins AK, LaSalle JM, Beckett L, Li Y, et al. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer. 2002;95(5):1009-15. doi: 10.1002/cncr.10808. [PubMed: 12209684].
  • 5. Rosai J. Rosai and Ackerman's surgical pathology. Elsevier Health Sciences; 2011.
  • 6. Bazley LA, Gullick WJ. The epidermal growth factor receptor family. Endocr Relat Cancer. 2005;12 Suppl 1:S17-27. doi: 10.1677/erc.1.01032. [PubMed: 16113093].
  • 7. Dabbs DJ. Diagnostic immunohistochemistry. Elsevier Health Sciences; 2013.
  • 8. Carneiro BA, Meeks JJ, Kuzel TM, Scaranti M, Abdulkadir SA, Giles FJ. Emerging therapeutic targets in bladder cancer. Cancer Treat Rev. 2015;41(2):170-8. doi: 10.1016/j.ctrv.2014.11.003. [PubMed: 25498841].
  • 9. Gorgoulis VG, Barbatis C, Poulias I, Karameris AM. Molecular and immunohistochemical evaluation of epidermal growth factor receptor and c-erb-B-2 gene product in transitional cell carcinomas of the urinary bladder: a study in Greek patients. Mod Pathol. 1995;8(7):758-64. [PubMed: 8539234].
  • 10. Sauter G, Haley J, Chew K, Kerschmann R, Moore D, Carroll P, et al. Epidermal-growth-factor-receptor expression is associated with rapid tumor proliferation in bladder cancer. Int J Cancer. 1994;57(4):508-14. [PubMed: 8181854].
  • 11. Wang C, Liu X, Wang L, Chen D, Tan Z, Wang Z, et al. [p16, p53 and c-erbB-2 gene expression in bladder carcinoma]. Zhonghua Bing Li Xue Za Zhi. 2000;29(1):20-3. [PubMed: 11866886].
  • 12. Ravery V, Grignon D, Angulo J, Pontes E, Montie J, Crissman J, et al. Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer. Urol Res. 1997;25(1):9-17. [PubMed: 9079740].
  • 13. Cheng L, Davison DD, Adams J, Lopez-Beltran A, Wang L, Montironi R, et al. Biomarkers in bladder cancer: translational and clinical implications. Crit Rev Oncol Hematol. 2014;89(1):73-111. doi: 10.1016/j.critrevonc.2013.08.008. [PubMed: 24029603].
  • 14. Zhao J, Xu W, Zhang Z, Song R, Zeng S, Sun Y, et al. Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis. Int Urol Nephrol. 2015;47(1):87-94. doi: 10.1007/s11255-014-0866-z. [PubMed: 25384433].
  • 15. Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997-4013. doi: 10.1200/JCO.2013.50.9984. [PubMed: 24101045].
  • 16. Ismail NEH, El-Nagar SI, Khodeir MM, Ahmed MM. Immunohistochemical study of HER-2/neu expression in urothelial bladder carcinoma. Acad Int J Cancer Res. 2015;8(3):35-9.
  • 17. Nedjadi T, Al-Maghrabi J, Assidi M, Dallol A, Al-Kattabi H, Chaudhary A, et al. Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques. BMC Cancer. 2016;16:653. doi: 10.1186/s12885-016-2703-5. [PubMed: 27539085].
  • 18. Behzatoglu K, Yorukoglu K, Demir H, Bal N. Human Epidermal Growth Factor Receptor 2 Overexpression in Micropapillary and Other Variants of Urothelial Carcinoma. Eur Urol Focus. 2016. doi: 10.1016/j.euf.2016.06.007. [PubMed: 28753766].
  • 19. Charfi S, Khabir A, Mnif H, Ellouze S, Mhiri MN, Boudawara-Sellami T. Immunohistochemical expression of HER2 in urothelial bladder carcinoma and its correlation with p53 and p63 expression. J Microsc Ultrastruct. 2013;1(1):17-21. doi: 10.1016/j.jmau.2013.06.001.
  • 20. Skagias L, Politi E, Karameris A, Sambaziotis D, Archondakis A, Vasou O, et al. Prognostic impact of HER2/neu protein in urothelial bladder cancer. Survival analysis of 80 cases and an overview of almost 20 years' research. J BUON. 2009;14(3):457-62. [PubMed: 19810139].
  • 21. Kruger S, Weitsch G, Buttner H, Matthiensen A, Bohmer T, Marquardt T, et al. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int J Cancer. 2002;102(5):514-8. doi: 10.1002/ijc.10731. [PubMed: 12432555].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments